2018 American Transplant Congress
Treatment Outcomes of FSGS Recurrence
Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…2018 American Transplant Congress
modified DFPP Can Eliminate Donor-Reactive IgG Antibody with Preserving Fibrinogen before Kidney Transplantation
BACKGROUND: Elimination of preexisting IgG antibodies against donor antigen is an important role before antibody-incompatible (i.e. ABO-incompatible and donor-specific antibody positive) kidney transplantation. Plasma exchange…2018 American Transplant Congress
How Safe is Crossing the ABO Blood Group Barrier? A Meta-Analysis to Determine the Additive Risk of ABO-Incompatible Kidney Transplantation
Nephrology and Kidney Transplantation, Erasmus Medical Center, Rotterdam, Netherlands.
Background ABO blood group-incompatible (ABOi) kidney transplantation is considered a safe procedure, with non-inferior outcomes in large cohort studies. Its contribution to living kidney transplantation…2018 American Transplant Congress
The Inhibitory Effect of Plasma on Activation of Lymphocytes from Kidney Transplants is Significantly More Severe in Tacrolimus Based Regimen: What Implications for Plasma Exchange Role in Anti-Rejection Therapy?
Background:Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented. However, trial…2018 American Transplant Congress
Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute
Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
INTRODUCTION: An ABO incompatible kidney transplant (ABOiKT) requires desensitization (DS). The ways of DS have been changed chronologically and the outcome could have been subsequently…2018 American Transplant Congress
Long-Term Success of Treatment for Cardiac Transplant AMR May Depend Upon Suppressing Class II Donor Specific Antibodies
Antibody mediated rejection (AMR) in cardiac transplant (tspt) patients (pts) is primarily mediated by donor specific antibodies (DSAs) and associated with reduced long-term graft survival.…2018 American Transplant Congress
Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients
Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…2018 American Transplant Congress
Recurrence of Focal Segmental Glomerulosclerosis (FSGS) and Response to Prolonged Plasmapheresis Therapy: A Single Center Pediatric Experience
FSGS is the most common glomerular cause of ESKD in pediatric patients. The risk of recurrence after kidney transplant (KT) is 30-60%, and half of…2018 American Transplant Congress
Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients
Purpose: Evaluate the efficacy and safety of acute antibody mediated rejection (AMR) treatment modalities in pediatric kidney transplant recipients (KTR).Methods: A single-center retrospective chart review…
American Transplant Congress abstracts